In recent months, Landauer (NYSE:LDR)'s price has been on a strong downtrend, losing 19% year-to-date, and 25% from its February 2013 peak. This is due mainly to pressured earnings from aggressive acquisitions (IZI Medical, 2011) and numerous internal upgrades (especially in its IT platforms). This have led to investors being uncertain about the future prospects of the company, pushing the company's stock price lower. In this article, I will analyze the company, and investigate why the company may be worth buying as a turnaround play.
Before going in-depth into Landauer's business, here are a few key figures and financials.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|